Media headlines about Emergent Biosolutions (NYSE:EBS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.1232187608414 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- New Strong Buy Stocks for December 1st (finance.yahoo.com)
- Insider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 47,983 Shares of Stock (americanbankingnews.com)
- Emergent BioSolutions to Host 2017 Analyst & Investor Day (finance.yahoo.com)
- Treichl Sees Central Banks Taking Over Bitcoin (finance.yahoo.com)
- Emergent BioSolutions Larger Than S&P 500 Component Lennar Corporation (nasdaq.com)
Shares of Emergent Biosolutions (NYSE:EBS) opened at $42.36 on Wednesday. Emergent Biosolutions has a 52-week low of $26.16 and a 52-week high of $44.97. The stock has a market capitalization of $1,815.19, a PE ratio of 23.20, a PEG ratio of 1.21 and a beta of 1.24. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The business had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same period in the previous year, the company earned $0.56 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. research analysts predict that Emergent Biosolutions will post 1.64 EPS for the current year.
A number of research analysts have commented on EBS shares. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $48.00 price objective on the stock in a research note on Tuesday, November 28th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $46.00.
In other news, Chairman Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $37.50, for a total transaction of $616,462.50. Following the sale, the chairman now directly owns 1,605,216 shares of the company’s stock, valued at $60,195,600. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronald Richard sold 22,415 shares of Emergent Biosolutions stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $40.00, for a total value of $896,600.00. Following the sale, the director now directly owns 24,676 shares in the company, valued at $987,040. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 279,632 shares of company stock worth $11,288,315. Corporate insiders own 16.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://ledgergazette.com/2017/12/06/emergent-biosolutions-ebs-given-media-impact-rating-of-0-17.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.